CapsoVision (CV) Gross Margin (2024 - 2025)

CapsoVision (CV) reported Gross Margin of 49.87% for Q4 2025, down 36.0% on a YoY basis from 77.93% in Q4 2024, and down 7.81% sequentially from 54.1% in Q3 2025.

CapsoVision (CV) Gross Margin (2024 - 2025) Analysis & Trends

CapsoVision (CV) has 2 years of Gross Margin data on file, last reported at 49.87% in Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 36.0% year-over-year to 49.87%; the trailing twelve-month figure through Dec 2025 stood at 52.12% (changed N/A YoY), and the FY2025 full-year result was 52.92%, down 132.0% from the prior year.
  • Gross Margin eased to 49.87% in Q4 2025, from 54.1% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 56.0% in Q2 2024 to a low of 49.87% in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 56.20%
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 63.29%
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 65.35%
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 69.46%
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 78.01%
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 62.95%
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 45.22%
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 38.53%
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 CapsoVision 162.07 Mn 151.95 Mn 1.95 Mn 49.87%

Historic Data

Download Data
DateValue
Dec 31, 2025 49.87%
Sep 30, 2025 54.10%
Jun 30, 2025 54.63%
Dec 31, 2024 50.23%
Sep 30, 2024 55.87%
Jun 30, 2024 56.00%